Northern Trust Corp Has $1.60 Million Stake in Genocea Biosciences, Inc. (GNCA)

Northern Trust Corp grew its stake in Genocea Biosciences, Inc. (NASDAQ:GNCA) by 642.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 306,597 shares of the biotechnology company’s stock after purchasing an additional 265,328 shares during the quarter. Northern Trust Corp owned about 1.08% of Genocea Biosciences worth $1,601,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Ameriprise Financial Inc. lifted its stake in shares of Genocea Biosciences by 11.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 2,300 shares during the period. Geode Capital Management LLC lifted its stake in shares of Genocea Biosciences by 4.7% in the 1st quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock valued at $903,000 after purchasing an additional 6,708 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Genocea Biosciences in the 2nd quarter valued at $100,000. State of Wisconsin Investment Board acquired a new position in shares of Genocea Biosciences in the 2nd quarter valued at $125,000. Finally, Rhumbline Advisers acquired a new position in shares of Genocea Biosciences in the 2nd quarter valued at $157,000. 34.74% of the stock is currently owned by institutional investors.

GNCA has been the topic of a number of analyst reports. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Monday, October 16th. Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 price target on shares of Genocea Biosciences in a research note on Thursday, November 2nd. Stifel Nicolaus downgraded Genocea Biosciences from a “buy” rating to a “hold” rating and cut their price target for the company from $15.00 to $2.50 in a research note on Monday, September 25th. Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, September 26th. Finally, ValuEngine downgraded Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $6.06.

Shares of Genocea Biosciences, Inc. (GNCA) opened at $1.18 on Monday. Genocea Biosciences, Inc. has a 12 month low of $1.03 and a 12 month high of $7.29. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same period last year, the business earned ($0.45) earnings per share. equities research analysts predict that Genocea Biosciences, Inc. will post -1.91 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Northern Trust Corp Has $1.60 Million Stake in Genocea Biosciences, Inc. (GNCA)” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/12/04/northern-trust-corp-has-1-60-million-stake-in-genocea-biosciences-inc-gnca.html.

Genocea Biosciences Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences, Inc. (NASDAQ:GNCA).

Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

What are top analysts saying about Genocea Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit